Real world clinical performance of the zotarolimus eluting coronary stent system in Chinese patients: a prospective, multicenter registry study

Early clinical trials with the Endeavor zotarolimus eluting stent (ZES) in western populations demonstrated low rates of target lesion revascularization with a favorable safety profile including low late stent thrombosis with up to 5 years of follow-up. The aim of this clinical registry study was to evaluate real world clinical performance of the ZES coronary system in Chinese patients.

2016

08-12

Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery

We aimed to investigate short-term outcomes of the XINSOEB bioresorbable sirolimus-eluting scaffold in human coronary artery.

2016

08-12

Scientists say human heart will be 3D printed within five years

Tencent Science News (Yuyou / Compilation) According to the British Daily Mail, 3D printers have long been used in the medical field, from human ears to functional valves. Currently, American scientists are using 3D printers to try to create a complete human heart.

2016

06-24

China Heart Stent Industry Development Report

According to the annual reports of relevant companies and the information of the Cinda Securities Research and Development Center, in 2013, 454,505 people in China underwent percutaneous coronary intervention (PCI), with an average of 1.51 stents placed. That is, in this year alone, China alone used 686 303 brackets. If calculated at an average of 20 mm per bracket, the brackets are nearly 14 kilometers together.

2015

08-27

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.

This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS.

2015

08-04

Outcomes with bioabsorbable vascular scaffolds versus everolimus-eluting stents Insights from randomized trials

Bioresorbable vascular scaffolds (BVS) have been shown to be non-inferior to second generation drug eluting stents in recent clinical trials. However, the trials were not powered for individual endpoints and there is concern for increased device thrombosis with BVS.

2015

08-04

Everolimus-eluting bioresorbable vascular scaff olds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled

Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease treated with percutaneous revascularisation.

2015

08-04

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimuseluting metallic stents in patients with coronary artery disease: ABSORB Japan

superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown.

2015

08-03

2014 World 3D Printing Technology Industry Conference ended successfully

As a cutting-edge and highly pioneering technology, 3D printing technology is rapidly entering our lives, attracting extensive attention from government organizations at all levels, enterprises and all walks of life.

2014

06-24

3D printing can meet the needs of personalized products

Tencent Technology News May 31, 2013 News, the first World 3D Printing Technology Industry Conference was held on May 29-31 at the China World Hotel in Beijing. Liu Qing, chairman of the board, delivered a speech at the meeting. Liu Qing said that 3D printing can precisely control the size of the pores of the scaffold, and can be used as cell culture scaffolds and implantable products, which is the advantage of 3D printing at present.

2014

04-30

< 1234 > proceed page

Company Information

Beijing Advanced Medical Technologies, Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel：010-6297-7955           E-Mail：amt@ametcorp.com

Picture Name

WeChat Contact

@Copyright 2022 Beijing Advanced Medical Technologies, Inc. All rights reserved

京ICP备11028039号   Powered by: www.300.cn   SEO